# Viktor Grünwald

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/viktor-grunwald/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,463 |
| Field | Renal cell carcinoma treatment |
| h-index | 56 |
| i10-index | 197 |
| Last Known Institution | Deutsche Schmerzgesellschaft |
| OpenAlex ID | https://openalex.org/A5001987856 |
| ORCID iD | https://orcid.org/0000-0003-2083-7687 |
| Works | 643 |

## Researcher papers

- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/renal-cell-carcinoma-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/quality-of-life-in-patients-with-advanced-renal-cell-carcinoma-given-nivolumab/)
- [Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-plus-ipilimumab-versus-placebo-for-localised-renal-cell/)
- [Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/)
- [Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Deutsche Schmerzgesellschaft](https://scholariq.org/institutions/deutsche-schmerzgesellschaft/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.